Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026
Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Fineline Cube Feb 11, 2026
Company Deals Digital

Takeda Enters $1.7 Billion AI Drug Discovery Partnership with Iambic Therapeutics

Fineline Cube Feb 11, 2026
Company Deals

Hemony Pharma Partners with Insud Pharma to Advance Fourth-Generation Oral Contraceptive in China

Fineline Cube Feb 10, 2026
Company Deals

Overseas Pharma Partners with South American Pharma Group on Global Extended-Release Drug Development

Fineline Cube Feb 10, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial

Fineline Cube Feb 11, 2026
Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Fineline Cube Feb 11, 2026
Policy / Regulatory

NHSA Releases Guide on Volume-Based Procurement Drug Equivalents

Fineline Cube Sep 22, 2022

The National Healthcare Security Administration (NHSA) has reportedly released a reference guide for industry players,...

Company Drug

Zelgen Biopharmaceuticals Gains NMPA Approval for Jacktinib Clinical Trial in SLE

Fineline Cube Sep 22, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...

Company Deals Policy / Regulatory

F-star Therapeutics’ Takeover by Sino Biopharmaceutical Delayed Amid CFIUS Review

Fineline Cube Sep 22, 2022

UK-based biotech F-star Therapeutics Inc. (NASDAQ: FSTX) announced in a stock exchange press release that...

Company Deals Digital

Shenzhen NeuroPlus Secures Seed Funding for Neuromodulation and Bioelectronic Medicine

Fineline Cube Sep 22, 2022

Shenzhen NeuroPlus has reportedly raised “tens of millions” of renminbi in a seed financing round...

Company

Merck KGaA Opens Viral Clearance Lab in Shanghai’s Biologics Testing Center

Fineline Cube Sep 22, 2022

German pharmaceutical giant Merck KGaA has opened a viral clearance (VC) laboratory as part of...

Company Deals

METiS Therapeutics In-Licenses Voronoi’s Pan-RAF Inhibitor Program

Fineline Cube Sep 22, 2022

Cambridge, Massachusetts-based METiS Therapeutics has unveiled its first in-license deal, signing with South Korea’s Voronoi...

Policy / Regulatory

Heilongjiang Launches ‘Longjiang Huiminbao’ Supplementary Health Insurance Scheme

Fineline Cube Sep 22, 2022

Heilongjiang province has launched its first provincial-level supplementary commercial health insurance scheme, branded “Longjiang Huiminbao.”...

Company Deals

Immuno Cure BioTech Acquires Majority Stake in Shanghai Teresa Healthcare

Fineline Cube Sep 21, 2022

Hong Kong-based Immuno Cure BioTech has announced the acquisition of a controlling 92.6% stake in...

Company Drug

Lepu Biotechnology’s MRG003 Receives Orphan Drug Designation from FDA

Fineline Cube Sep 21, 2022

China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received orphan drug...

Company Deals

Kamari Pharma Completes $8M Investment from Chinese Fund GIBF2

Fineline Cube Sep 21, 2022

Israel-based Kamari Pharma has announced the completion of an $8 million investment from the Chinese...

Company Drug

Joincare’s Modified Drug XYP-001 Gains NMPA Approval for IPF Trial

Fineline Cube Sep 21, 2022

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has announced that it has received...

Company Deals

Koutech Robotics Secures Series A Funding for Surgical Innovation

Fineline Cube Sep 21, 2022

China-based Koutech Robotics (Shanghai) Co., Ltd, a leading ultra-micro, high-precision surgical robot platform company, has...

Company Drug

CARsgen Therapeutics Presents Positive Phase Ib/II Data for CT053 at CAR-TCR Summit

Fineline Cube Sep 21, 2022

China-based CARsgen Therapeutics Holdings Ltd presented the results of a multi-center, open-label Phase Ib/II study...

Company Deals

Joincare Pharmaceuticals Prices GDRs on SIX Swiss Exchange

Fineline Cube Sep 21, 2022

China-based Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) has priced its Global Depository Receipts...

Company

Northeast Pharmaceutical to Invest in Shanghai Subsidiary for ADC and CAR-T Development

Fineline Cube Sep 21, 2022

China-based Northeast Pharmaceutical Co., Ltd (SHE: 000597) has announced plans to invest RMB 500 million...

Policy / Regulatory

Beijing Designates 923 Medical Entities for National Reimbursement Drug List

Fineline Cube Sep 21, 2022

The Beijing Municipal Medical Insurance Bureau has released a notification indicating that a total of...

Company

Lee’s Pharmaceutical Reports H1 Revenue Growth Amid Product Portfolio Shift

Fineline Cube Sep 20, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its H1 2022 interim financial report,...

Company Drug

Junshi Biosciences’ Tuoyi Approved for First-Line NSCLC Treatment in China

Fineline Cube Sep 20, 2022

China’s Center for Drug Evaluation (CDE) has approved Junshi Biosciences’ (HKG: 1877, SHA: 688180) Tuoyi...

Company Drug

Sun-Novo’s STC007 Gains NMPA Approval for Postoperative Pain Study

Fineline Cube Sep 20, 2022

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd has announced that it has received approval from...

Company Deals

WuXi Biologics Partners with Elpiscience for Macromolecule Development

Fineline Cube Sep 20, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced multiple...

Posts pagination

1 … 579 580 581 … 622

Recent updates

  • China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million
  • Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial
  • Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder
  • Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device
  • Eisai Biogen’s LEQEMBI Subcutaneous Autoinjector Wins NMPA Priority Review in China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Company Drug

Changchun High-Tech’s GenSci136 Wins NMPA Approval for IgA Nephropathy Clinical Trial

Company Drug

Sanofi’s Wayrilz Wins FDA Breakthrough and Japan Orphan Designation for Rare Blood Disorder

Company Deals

Tangji Medtech Files Hong Kong IPO for First NMPA-Approved Endoscopic Obesity Device

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.